...老牌的生物制剂，包括Procrit、Genotropin 等，开始面临主要专利过期的压力，为了因应可能面临的潜在 生技学名药 ( Biogenerics )的压力，价格调降与其他的竞争因素，都可能影响市场的成长速度。
基于16个网页-相关网页
So the real question is what would-be manufacturers of biogenerics will be required to do to win approval here.
所以真正的问题是那些希望成为非专利生物技术药物生产者的公司需要做出努力来赢得当局者的允许。
youdao
Biogenerics also present an opportunity for the bigger firms like Teva, which have the capability to duplicate larger molecule drugs.
FORBES: Four Sexy Cougar Stocks
David Williams is saddened by U.S. biogenerics policy.
FORBES: Health Wonk Review Review: On Vinson, Ryan, & Gawande
It's a different story with biogenerics.
FORBES: Magazine Article
应用推荐
模块上移
模块下移
不移动